Furmonertinib Approved for First-Line Treatment
Today, Shanghai Allist Pharmaceuticals Co., Ltd. (stock code: 688578) announced that Furmonertinib had been approved by the National Medical Products Administration (NMPA) of China...
Today, Shanghai Allist Pharmaceuticals Co., Ltd. (stock code: 688578) announced that Furmonertinib had been approved by the National Medical Products Administration (NMPA) of China...
On 25 November 2021, 3D Medicines (Beijing) Co., Ltd. (3DMed), Alphamab Oncology, and Simcere Pharmaceutical Group Limited (Simcere) jointly announced that Envafolimab (KN035), the...
Shanghai, China – March 19, 2020 – Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”), a leading biopharmaceutical company in China, announced that the National Med...